10.06.2011 • NewsHans WijersAkzoNobelPeople

Hans Wijers to Leave AkzoNobel in 2012

Current Sulzer CEO Ton Büchner (l.) is slated to take over as CEO of AkzoNobel...
Current Sulzer CEO Ton Büchner (l.) is slated to take over as CEO of AkzoNobel when Hans Wijers steps down in 2012.

AkzoNobel has announced that CEO Hans Wijers will be stepping down with effect from the company's annual general meeting (AGM) in 2012. Sulzer President and CEO Ton Büchner is slated to take over the helm of the Dutch company, pending AGM approval.

Wijers joined AkzoNobel as member of the board of management in October 2002, and was subsequently appointed CEO in May 2003. The company credits him with having improved its pharma business, focusing its chemicals businesses and successfully growing the coatings business.  

Büchner  has been CEO of Sulzer since 2007. He joined Sulzer in 1994 and has held a number of operational and leadership roles across the company including the presidencies of two of its divisions, Sulzer Turbomachinery Services and Sulzer Pumps. He was also chief representative and responsible for Sulzer operations in China. He will join AkzoNobel in January.

 

Company

Logo:

AkzoNobel

Christian Neefestraat 2
1077 WW Amsterdam
Netherlands

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.